Skip to content

Management of Skin Graft Donor Site Wound in Aged Patient

Management of Skin Graft Donor Site Wound in Aged Patient

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05371171
Enrollment
15
Registered
2022-05-12
Start date
2018-03-13
Completion date
2019-09-03
Last updated
2022-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Regrafting; Donor Site of Skin Grafting; Vancouver Scar Scale

Brief summary

The complication of donor site in skin grafting often acts as a causing factor for extended treatment period. The elderly individuals tend to be afflicted by impaired wound healing. Herein, the investigators presented the outcome of skin regrafting in the elderly patients.

Interventions

PROCEDUREskin graft

In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, & Nephew\] was placed on the regrafted skin for fixation

PROCEDUREno skin graft

In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, & Nephew\] was placed on the regrafted skin for fixation

Sponsors

Taipei Medical University WanFang Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Months to 99 Months
Healthy volunteers
No

Inclusion criteria

1. All patient who need to perform skin grafting surgery

Exclusion criteria

1. All patient who cannot be half or general anesthetized 2. severe comorbidities

Design outcomes

Primary

MeasureTime frame
healing timethree months

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026